ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 28317872

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.

Fu J and 13 others. Acta Pharmacol Sin, 2017. Cited by 43 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Papers, record 28317872. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28317872

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
PubMed
Journal
Acta Pharmacol Sin
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
43
iCite
Relative citation ratio, by iCite
1.15
iCite
Revised in PubMed
2018-11-13
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fu JJie
2Wang FFang
3Dong LHLi-Hou
4Zhang JJing
5Deng CLCheng-Lian
6Wang XLXue-Li
7Xie XYXin-Yao
8Zhang JJing
9Deng RXRuo-Xian
10Zhang LBLi-Bo

1 to 10 of 14Source PubMed

See all 14 authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Animals
B7-H1 Antigen
Cell Proliferation
Humans
Macaca fascicularis
Marmota
Mice
Programmed Cell Death 1 Ligand 2 Protein
Protein Binding
T-Lymphocytes

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04005170Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerBackgroundClinicalTrials.gov
NCT04006041Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerResultsClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124,391,505Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.PLoS Pathog2014https://conductscience.org/library/papers/24391505PubMed
221,477,291Pro- and anti-apoptotic CD95 signaling in T cells.Cell Commun Signal2011https://conductscience.org/library/papers/21477291PubMed
316,954,372PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.J Exp Med2006https://conductscience.org/library/papers/16954372PubMed
420,516,446Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol2010https://conductscience.org/library/papers/20516446PubMed
522,658,127Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012https://conductscience.org/library/papers/22658127PubMed
625,922,740The use of correlation functions in thoracic surgery research.J Thorac Dis2015https://conductscience.org/library/papers/25922740PubMed
723,980,172Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/23980172PubMed
824,403,232PD-1 as a potential target in cancer therapy.Cancer Med2013https://conductscience.org/library/papers/24403232PubMed
919,078,956Enhancing SIV-specific immunity in vivo by PD-1 blockade.Nature2009https://conductscience.org/library/papers/19078956PubMed
1025,704,439Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.Lancet Oncol2015https://conductscience.org/library/papers/25704439PubMed

1 to 10 of 13

See all 13 references

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.

PMIDTitleJournalYearIn PapersSource
42,870,845Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42870845PubMed
41,158,245Efficacy and safety of toripalimab in the treatment of patients with non-small cell lung cancer: a systematic review and meta-analysis.Transl Cancer Res2025https://conductscience.org/library/papers/41158245PubMed
39,358,463Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.Cancer Immunol Immunother2024https://conductscience.org/library/papers/39358463PubMed
38,915,766Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.Front Med (Lausanne)2024https://conductscience.org/library/papers/38915766PubMed
38,862,251Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.J Immunother Cancer2024https://conductscience.org/library/papers/38862251PubMed
38,836,437Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma.Diagn Interv Radiol2025https://conductscience.org/library/papers/38836437PubMed
38,617,189Structure and function of therapeutic antibodies approved by the US FDA in 2023.Antib Ther2024https://conductscience.org/library/papers/38617189PubMed
37,201,046
Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
J Gastrointest Oncol2023https://conductscience.org/library/papers/37201046PubMed
36,928,584Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36928584PubMed
36,206,498Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).J Clin Oncol2023https://conductscience.org/library/papers/36206498PubMed

1 to 10 of 30

See all 30 cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
IFNG3,458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
PDCD1LG280,380PubTator's text mininghttps://conductscience.org/library/genes/80380NCBI Gene
TNF7,124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Results1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
PACLITAXELCHEMBL428647Results1https://conductscience.org/library/drugs/CHEMBL428647ChEMBL
TORIPALIMABCHEMBL4297843Results1https://conductscience.org/library/drugs/CHEMBL4297843ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28317872

GET https://conductscience.org/api/papers/v1/28317872/cited_by?page=2

API referenceFor AI assistants